Futures and Commodity Market News

May 04, 2024 (MENAFN via COMTEX) --

(MENAFN - Investor Brand Network) Aditxt
(NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has entered into securities purchase agreements. The agreements are for the purchase and sale of 4,186 shares of the Company's Series C-1 Convertible Preferred Stock and 4,186 shares of the Company's D-1 Preferred Stock, as well as warrants to purchase approximately 1.65 million shares of common stock in a private placement. According to the announcement, the shares of Series C-1 Convertible Preferred Stock are valued at $1,000 per share and are initially convertible into approximately 1.65 million shares of common stock at a conversion price of $2.47 per share. The Series D-1 Preferred Stock allows the holders to vote, along with the holders of the company's common stock, on proposals related to shares of common stock that Aditxt is authorized to issue. The warrants will be exercisable six months after the initial issuance date at an exercise price of $2.595 per share and will expire five years from the date of issuance. The company plans to use the funds to pay for obligations related to its merger agreement with Evofem Biosciences Inc. as well as for working capital and other general corporate purposes. The private placement is expected to close on or about May 6, 2024, and will be subject to customary closing conditions. Dawson James Securities is acting as the exclusive placement agent for the offering.

To view the full press release, visit

About Aditxt Inc.

Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt's ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to"Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, including Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies. Adivir(TM) Inc. focuses on enhancing national and population health and impacting public health globally. Pearsanta(TM) Inc. delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia. For more information, please visit .

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company's newsroom at

About TinyGems

TinyGems
is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text"Gems" to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published:
/Disclaimer

TinyGems
Los Angeles, CA

310.299.1717 Office
...

TinyGems is powered by
IBN

MENAFN03052024000224011066ID1108171372

COMTEX_451866992/2604/2024-05-04T02:13:27